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Abstract
Background. Levocetirizine, active R (−) enantiomer of cetirizine, is an orally active and selective H1 re-
ceptor antagonist used medically as an anti-allergic. Allergic rhinitis is a symptomatic disorder of the nose 
induced by inflammation mediated by immunoglobulin E (IgE) in the membrane lining the nose after al-
lergen exposure.
Objectives. The purpose of the present study was to prepare rapidly disintegrating tablets of levocetirizine 
after its complexation with β-cyclodextrin (β-CD).
Material and methods. Levocetirizine–β-CD complex tablets were prepared by direct compression 
technique using 3 synthetic superdisintegrants in different proportions. Development of  the formulation 
in the present study was mainly based on the concentration of superdisintegrants and the properties of the 
drug. Nine batches of tablets were formulated and evaluated for various parameters: drug content, weight 
variation, water absorption ratio, wetting time, in vitro disintegration, hardness, friability, thickness unifor-
mity, and in vitro dissolution.
Results. A Fourier-transform infrared spectroscopy (FTIR) study showed that there were no significant in-
teractions between the drug and the excipients. The prepared tablets were good in appearance and sho-
wed acceptable results for hardness and friability. The in vitro disintegrating time of the formulated tablet 
batches was found to be 15–35 s percentage and the drug content of tablets in all formulations was found 
to be between 90–102%, which complied with the limits established in the United States Pharmacopeia.
Conclusions. Complexation of levocetirizine with β-CD significantly improves the solubility of the drug. 
The disintegration time of the tablets was decreased with an increase in superdisintegrant amount. The ta-
blets (batch CPX5) had a minimum disintegration time of 20 s and 99.99% of the drug was released wi-
thin 10 min.
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Introduction 
Tablets are the most widely accepted dosage forms.1,2 
Rapidly disintegrating tablets (RDTs) are gaining more 
popularity as they can be administered without the need 
to be swallowed with water, and they are dissolved or eas-
ily disintegrated in the mouth within a few seconds. The 
drug is released immediately when the tablet is placed on 
the tongue. The RDTs are in ever-increasing demand com-
pared to liquid dosage forms due to the ease of handling, 
accurate dose and good stability during storage. They 
improve the oral bioavailability of drugs as compared to 
conventional tablets. The released drug will be absorbed 
from the whole gastrointestinal tract and thus the oral 
bioavailability will improve.3 The disintegration time for 
orally rapid disintegrating tablets is generally considered 
to be less than 60 s.4,5 Various RDTs have been reported 
to improve patient compliance and bioavailability, such 
as dispersible tablets, rapidly disintegrating tablets, orally 
disintegrating tablets, quick disintegrating tablets, rapid 
dissolving tablets, porous tablets, quick melt tablets, etc.6
Rapidly disintegrating drug delivery systems (RDDDS) 
offer several benefits such as easy administration to chil-
dren and elderly patients having difficulties swallowing 
(dysphagia) and in the case of tremors or mental retarda-
tion condition.7 The RDDDS are also useful for local ac-
tion such as a local anesthetic for toothaches, oral ulcers, 
cold sores, or teething.8 The RDTs can be prepared using 
conventional methods like direct compression, wet gran-
ulation, moulding, spray drying, freeze-drying, and subli-
mation. Proper choice of superdisintegrants and consis-
tency in its performance are of critical importance to the 
formulation development of  RDTs.9 Examples of  some 
widely used superdisintegrants are modified starch (sodi-
um starch glycolate), modified cellulose (croscarmellose) 
and cross-linked polyvinylpyrrolidone (crospovidone).10
Basic considerations in formulating RDTs are palat-
ability, aqueous solubility, hygroscopicity, and mechani-
cal strength.11 These systems are made to disintegrate or 
dissolve in the oral cavity, which may lead to the sensa-
tion of taste. Thus, taste masking of the bitter drugs be-
comes critical to patient compliance. Water solubility 
is another critical parameter that needs to be examined 
carefully during the manufacturing of RDTs. The forma-
tion of a eutectic mixture of most of the BCS (biopharma-
ceutical classification system) class I and III drugs leads to 
a depression in freezing point. This results in the forma-
tion of a glassy solid mass which can be easily sublimated 
with drying. Drying of the formed glassy solid mass may 
cause it to collapse due to the loss of  supporting struc-
tures.12 Normal storage conditions may affect the physical 
integrity of  RDTs, hence specialized packaging is need-
ed to protect them from environmental conditions such 
as temperature and humidity. For rapid disintegration, 
RDTs are manufactured at low compression force. This 
may lead to the formation of a friable or brittle tablet. The 
handling of such products might be difficult and requires 
peel-off blister packing. The objective of compressed-tab-
let manufactures is to deliver the orally correct amount 
of  the drug in proper time and to the desired location 
while subsequently maintaining its chemical integrity to 
that point. The aim of  the present study was to prepare 
RDTs of  levocetirizine to improve the drug stability and 
its therapeutic benefits.
Materials 
The levocetirizine was a generous gift from Cipla Ltd., 
Ahmedabad, India. β-cyclodextrin (β-CD) was purchased 
from Central Drug House (P) Ltd., New Delhi, India. Sodium 
starch glycolate (SSG), croscarmellose sodium (CMS), 
microcrystalline cellulose (MCC), crospovidone (CP), 
magnesium stearate, aerosol, and mannitol were pur-
chased from S.D. Fine Chem Ltd., Mumbai, India. All the 




Levocetirizine–β-CD complex (1:1 molar ratio) was pre-
pared using the kneading method. Briefly, an accurately 
weighed amount of the pure drug and β-CD was triturated 
in a clean and dry mortar with a small volume of the water-
methanol solvent system to make a thick slurry. The mass 
was uniformly mixed and dried at 40°C. The dried mass 
was grained and sifted through a mesh (100).12–15
Characterization  
of levocetirizine–β-CD complex 
UV spectroscopic study 
The confirmation of  complexation between the 
levocetirizine–β-CD was carried out by ultraviolet-visible 
spectrophotometrically (UV-visible spectrophotometer, 
3000+, LabIndia, Mumbai, India). Pure levocetirizine 
(10 mg) was dissolved in methanol (100 mL), filtered and 
analyzed at 231 nm after suitable dilution. Similarly, the 
same spectrum was taken for the levocetirizine–β-CD 
complex (containing 10 mg levocetrizine) at 233 nm. The 
change in absorbance of the drug in levocetirizine–β-CD 
complex was recorded.
Fourier-transform infrared spectroscopy 
A Fourier-transform infrared (FTIR) spectroscopy 
of pure levocetirizine, β-CD and levocetirizine–β-CD 
complex (1:1) was carried out by the FTIR peak match-
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ing method (IR-affinity-1; Shimadzu, Kyoto, Japan). 
Briefly, the samples were mixed with dried potassium 
bromide (KBr) and compressed into a  pellet using 
KBr press at 10  t. The pellets were scanned from 
4000–400 cm−1 at 4 cm−1 resolution. The complex for-
mation was evaluated by comparing the FTIR spec-
tra of  the drug–β-CD complex and that of  the pure 
drug.16,17
X-ray diffraction studies 
An X-ray diffraction study of  pure levocetirizine and 
the drug–β-CD complex (1:1) was done by X-ray pow-
der diffractometer (PW 3040/60 Xpert PRO; PANalyti-
cal, Almelo, the Netherlands) using Cu Kα radiations 
(λ = 1.5405980 Å), 40 mA current and 40 kV voltage. The 
samples were analyzed over 0–80 2θ range with a  scan 
step size of 2°/min.18
Powder characterization 
Determination of angle of repose 
The angle of repose was determined to know the flow 
properties of  granules using the funnel method. Briefly, 
the powder mix was allowed to pour from a funnel that 
can be raised vertically until a maximum cone height was 
obtained. The angle of repose (θ) was determined by mea-
suring the height (h) and radius (r) of the cone using the 
following formula19:
tan θ = h 
r 
The mean result of  triplicate measurements and the 
standard deviation (SD) were reported.
Determination of loose density 
Loose bulk density (LBD) is the ratio of powder weight 
in grams to the loose bulk volume [cm³]. A sample (5 g) 
was carefully introduced in a 10 mL graduated measur-
ing cylinder and LBD was determined using the following 
formula19:
loose bulk density = weight of powder [g]
bulk volume [cm3]
The mean result of triplicate measurements and the SD 
were reported.
Determination of tapped density 
For the determination of tapped density, a powder sample 
(5 g) was introduced in a 10 mL graduated measuring cylin-
der. The cylinder was dropped onto a flat surface 50 times 
from 2.5 cm height. Tapped bulk density was determined 
by applying the following formula19:
tapped density = weight of powder
tapped volume of powder
The mean result of triplicate measurements and the SD 
were reported.
Determination of the Hausner ratio 
Hausner ratio (HR) is an indirect index of ease of powder 
flow. Lower HR (<1.25) indicates better flow properties. 
It was determined by applying the following formula19:
Hausner ratio = tapped density 
bulk density 
The mean result of triplicate measurements and the SD 
were reported.
Determination of void volume 
The volume of the space between particles was deter-
mined by applying the following formula:
void volume = bulk volume − tapped volume
The mean result of triplicate measurements and the SD 
were reported.
Determination of Carr’s compressibility index 
Carr’s compressibility index is determined using den-
sity measurements. A  particle bed having more com-
pressibility is less flowable and vice versa. Carr’s com-
pressibility index [%] was determined by the following 
formula19:
Carr’s index = tapped density – bulk density × 100
tapped density
The mean result of triplicate measurements and the SD 
were reported.
Determination of percentage porosity 
The percent porosity of the granules of each prepared 
batch was determined using the following formula:
porosity [%] = 1 –
Vp × 100
Vb
Where Vb is the bulk volume, and Vp is the particle vol-
ume. The mean result of triplicate measurements and the 
SD were reported.
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Preparation and evaluation  
of rapidly disintegrating tablets 
Rapidly disintegrating tablets of  levocetirizine were 
prepared by direct compression method. Croscarmellose 
sodium (CCS), sodium starch glycolate (SSG) and crospo-
vidone (CP) were used as superdisintegrants. The β-CD 
was used as a complexing agent to improve the dissolu-
tion of  the drug. Microcrystalline cellulose (MCC) was 
used as a binder (Table 1). Drug–β-CD complex equiva-
lent to 5  mg of  the levocetirizine and all the excipients 
except magnesium stearate and aerosil were taken in 
a mortar and mixed. The powder mix was passed through 
a 80 sieve. Lubrication was done using magnesium stea-
rate and aerosil. The final blend was compressed into 
caplets using a  10-station compression machine (Mini-
press-1, Karnavati, Ahmedabad, India) to produce 120 mg 
tablets using 4 mm diameter die and punches.20
The prepared tablets were evaluated for both non-offi-
cial and official tests. Tablets from each batch were sub-
jected to the following tests.
General appearance 
The general appearance of  a  tablet, its visual identity 
and overall elegance is essential for patient’s acceptance. 
The tablet’s shape, size, color, presence or absence of an 
odor, and legibility of any identifying marking were stud-
ied as the general appearance characteristics.
Test for weight uniformity 
The United States Pharmacopeia (USP) procedure for 
the determination of uniformity of tablet weight was fol-
lowed. Twenty tablets from each batch were taken and 
weighed individually and collectively on a digital weighing 
balance (MAB 182; Wensar, Mumbai, India). The average 
weight of 20 tablets was calculated. The weight variation 
was calculated for USP limits, i.e., for an average weight 
of  80 mg or less, 80–250 mg and more than 250 mg; 
the maximum percentage differences allowed are 10%, 
7.5% and 5%, respectively. The mean result of  triplicate 
measurements and the SD were reported.21
Determination of tablet thickness 
The thickness of tablets was determined using vernier 
callipers. Twenty tablets from each batch were randomly 
selected for thickness measurements. The mean result 
of triplicate measurements and the SD were reported.
Determination of tablet hardness 
The resistance of tablets to chipping, abrasion or break-
age under the conditions of storage, transformation and 
handling depends on its hardness. The tablet hardness 
was determined by diametral compression using a  dial-
type Monsanto tablet hardness tester. A  tablet hardness 
of about 4–5 kg/cm² is considered adequate for mechani-
cal stability. The sampling was carried out in triplicate for 
each batch.
In vitro disintegration, dispersion and wetting test 
One tablet was placed in each tube of a USP tablet disin-
tegration test apparatus (ED–2 SAPO; Electrolab, Mum-
bai, India) and the basket rack was positioned in a  1  L 
beaker containing freshly prepared and cooled distilled 
water at 37 ±0.5°C. The time required for a complete dis-
integration of the tablet with no palpable mass remaining 
in the apparatus was measured. Dispersion time of  the 
tablet was recorded by placing 1 tablet from each batch 
in a Petri dish containing phosphate buffer (pH 6.8). For 
the determination of the wetting time of the tablet, a cir-
cular piece of  tissue paper (12 × 10.75 cm) folded twice 
was placed in a small Petri dish (internal diameter 6.5 cm) 
containing 10 mL of phosphate buffer (pH 6.8). A tablet 
was placed on the paper, and the time for complete wet-
ting was measured. The sampling was carried out in trip-
licate for each batch.22





















Levocetirizine–β-CD complex* 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5 14.5
SSG – – 10 11 12 – – 10 –
CMS 11 – – – – 10 11 – –
CP – 10 – – – – – – 10
Mg stearate 3 2 3 2 2 3 1 2 1
Aerosil 2 2 2 2 2 2 2 2 2
Mannitol 21.5 18.5 18.5 20 14.5 14.5 22 16.5 12.5
MCC 68 73 72 70 75 76 74 75 80
* Complex equivalent to 5 mg of levocetirizine; β-CD – β-cyclodextrin; SSG – sodium starch glycolate; CMS – croscarmellose sodium; CP – crospovidone; 
MCC – microcrystalline cellulose.
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Determination of water absorption ratio 
For the determination of water absorption ratio, a small 
piece of tissue paper (folded twice) was placed in a Petri 
dish containing distilled water (6  mL). The tablet was 
placed on the wet paper and the weight of the wet tablet 
was recorded. The water absorption ratio (R) was calcu-
lated using the following formulation22:
R = Wa – Wb × 100
Wb
where Wb and Wa are the weight of  the tablet before 
and after water absorption, respectively. The mean result 
of triplicate measurements and the SD were reported.
Determination of percentage friability 
A USP tablet friabilator (EF–2; Electrolab, Mumbai, 
India) was employed for the determination of  tablet fri-
ability. Pre-weighted tablets (20  tablets) were placed in 
the friabilator. The friabilator was rotated for 4  min at 
25 rpm. At the end of the test, the tablets were dusted and 
re-weighed. The loss in tablet weight was measured and 
the friability was calculated using the following formula:
friability [%] = weight after 100 counts × 100
initial weight
Determination of drug content 
Ten tablets of  levocetirizine from each batch were 
crushed and the mass equivalent to 1 tablet was taken and 
transferred to a  100 mL volumetric flask. Final volume 
was adjusted with phosphate buffer (pH 6.8). The mixture 
was shaken for 30 min in a water bath shaker incubator. 
The mixture was filtered and the filtrate was analyzed at 
233.00 nm after suitable dilutions using an ultraviolet-
visible spectrophotometer (3000+; Labindia, Mumbai, In-
dia). The mean result of triplicate measurements and the 
SD were reported.23 
X-ray diffraction study 
X-ray diffraction study of the prepared tablet (formula-
tion CPX5) was carried out similarly as for the pure drug 
and complex.
In vitro dissolution studies 
An in vitro dissolution study was carried out using USP 
tablet dissolution test apparatus II (DS 8000; Labindia, 
Mumbai, India) at 50 rpm in 900 mL of phosphate buffer 
(pH 6.8). The temperature was maintained at 37 ±0.5°C. 
The samples were withdrawn at predetermined time in-
tervals of 0 min, 2 min, 4 min, 6 min, and 10 min. Aliquots 
(5  mL) were withdrawn, filtered and analyzed spectro-
photometrically using a  UV spectrophotometer (3000+) 
at 233 nm. Complete sink condition was maintained by 
adding an equal amount of  fresh dissolution medium 
(37 ±0.5°C) after each sampling. The sampling study was 
carried out in triplicate for each batch. The kinetic study 
of drug release data was done by zero order (cumulative 
percentage drug released vs time) and first order (per-
centage drug retained vs time) plots.
Results and discussion 
Characterization  
of levocetirizine–β-CD complex
UV spectroscopic study 
The results showed no shift in the λmax of  levocetiri-
zine in the presence of β-CD complex (Fig. 1). The slight 
change in absorbance could be explained due to the 
changes in the solvent microenvironment and the transfer 
of the guest molecule of water in the β-CD cavity during 
complex formation.
Fig. 1. UV scan spectrum of the levocetirizine–β-cyclodextrin (β-CD) 
complex (A) and pure levocetirizine (B)
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Fourier-transform infrared spectroscopy 
A FTIR spectroscopy was carried out to investigate the 
possible interaction between levocetirizine and β-CD, if any. 
The FTIR spectrum of  levocetirizine, β-CD and physical 
mixture of  levocetirizine–β-CD complex are illustrated in 
Fig. 2. The chemical interaction between the levocetirizine–
β-CD leads to identifiable changes in the infrared profile 
of dispersion. In the present study, the FTIR spectrum of le-
vocetirizine showed characteristic peaks at 3641 cm–1 (OH 
stretching), 2785 cm–1 (CH2 stretching), 1718 cm–1 (stretch-
ing of ester carbonyl and –COOH groups), 1602 cm–1 (C=C), 
1479  cm–1 (ether group), 1319  cm–1 (C–N stretching), 
1085 cm–1 (C=O stretching), and 721 cm–1 (C–Cl stretch-
ing). In the case of  β-CD, stretching (broad) of  the O–H 
group was observed near 3227 cm–1. β-CD showed charac-
teristic peaks near 2928 cm–1 (antisymmetric and symmetric 
stretching of –CH2 group), 1642 cm–1 (O–C (2-bands) C=O 
(amide I band)), 1410 cm–1 (in plane bending) of OH, bend-
ing of α-CH2 and deformation of CH2), 1332 cm–1 in plane 
bending of OH), 1152 cm–1 (bending of C–C–C), 1077 cm–1 
and 1022  cm–1 (O–H (H-bonded), usually broad C–O), 
937 cm–1, 860 cm–1 and 753 cm–1 (stretching of =C–H and 
=CH2, bending and ring puckering of C–H) and 703 cm–1 
(cis–RCH=CHR). The ester carbonyl stretching bend of le-
vocetirizine shifted from 1718  cm–1 down to 1675  cm–1. 
This may be due to the intermolecular hydrogen bond-
ing between levocetirizine and β-CD. The peak due to the 
stretching vibration of the N–H bond near 3317 cm–1 in the 
dihydropyridine ring was broadened, nearly disappeared in 
complex spectra. A broad peak near 3227 cm–1 (–OH band 
of pure β-CD) was observed in the spectrum of the complex, 
indicating complex formation and inclusion of levocetirizine 
in the cavity of β-CD. The increment in intensity is due to 
the insertion of a benzene ring into the electron-rich cavity 
of β-CD, which increases electron density and leads to the 
increase in frequency. Thus, the FTIR spectrum proves the 
formation of the levocetirizine–β-CD complex.
X-ray diffraction 
An X-ray diffraction study was used to evaluate the 
physical state of pure levocetirizine and the drug within 
the levocetirizine–β-CD complex (1:1). The X-ray diffrac-
tograms of  pure levocetirizine and levocetirizine–β-CD 
complex are presented in Fig. 3. Levocetirizine has shown 
characteristic intense peaks at 2θ of 5.50, 6.50, 7.50, 8.32, 
10.58, 12.42, 13.54, 14.51, 15.21, 16.03, 16.94, 17.87, 18.98, 
19.20, 20.81, 21.54, 22.64, 23.84, 24.58, 25.24, 25.64, 26.23, 
27.64, 29.00, 29.94, 30.32, 31.11, 31.75, 33.34, 35.51, 35.85, 
36.35, 37.94, and 39.21 because of its crystalline state. In 
the levocetirizine–β-CD complex, the drug peaks are vis-
ible at 2θ of 4.78, 6.54, 7.33, 7.68, 8.27, 9.27, 9.98, 10.93, 
Fig. 3. X-ray diffraction patterns of pure levocetirizine (A)  
and levocetirizine–β-cyclodextrin (β-CD) complex (1:1) (B)
Fig. 2. Fourier-transform infrared spectroscopy (FTIR) spectrum 
of levocetirizine (A), β-cyclodextrin (β-CD) (B) and physical mixture 
of levocetirizine–β-cyclodextrin (β-CD) complex (C)
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12.742, 13.06, 14.90, 15.67, 16.32, 17.34, 18.30, 19.12, 
19.80, 21.03, 23.10, 24.57, 25.38, 26.85, 27.36, 29.71, 30.47, 
31.40, 32.18, 34.03, 35.03, 36.12, 37.69, 40.02, 41.03, and 
44.53, indicating the crystalline form of  the drug within 
the complex. The drug is not in amorphous form, other-
wise the drug peaks would have disappeared completely 
in the complex. However, the crystallinity of the drug has 
been decreased in the case of  the levocetirizine–β-CD 
complex as some of the peaks disappeared.
Evaluation of powder 
Angle of repose 
The angle of repose (θ) was calculated to know the flow 
properties of granules. Based on the particle size, powders 
are broadly classified as very fine, fine, moderately fine, 
moderately coarse, and coarse. The particles having size 
<100 mm tend to be more cohesive and less free-flowing. 
Larger particles have good flow properties. The cohesivity 
of powder decreases with the increase in particle size. The 
USP defined the range of angle of repose as: 25–30 for ex-
cellent flow, 31–35 for good, 36–40 for fair, 41–45 for pass-
able, 46–55 for poor flow, 56–65 for very poor flow, and 
>66 for considerably poor flow.24 In the present study, the 
value of angle of repose for all the batches ranged between 
23.93 ±0.22 to 30.04 ±0.23 (Table 2), indicating excellent 
flow potential of the blend. The powdered mass of the dif-
ferent formulations was found to be non-aggregating. The 
results are acceptable for tablet manufacturing purposes.
Bulk density 
The results of  bulk density are represented in Table 2. 
The bulk densities of all the batches were observed between 
0.45 ±0.27  g/cm³ and 0.56 ±0.38  g/cm³. The bulk density 
of batches CPX1 and CPX6 was found to be almost similar, 
indicating similar bulk volume and packing arrangements.
Tapped density 
The results of tapped density are represented in Table 2. 
The tapped density was observed between 0.54 ±0.32 g/mL 
and 0.69 ±0.28 g/mL. The difference in the values of bulk 
density and tapped density indicates very little or no 
change in powder volume even after 50 tappings.
Hausner ratio 
The HR is an indication of flow properties of the pow-
der blend. A  HR <1.25 indicates good flow properties, 
1.25–1.50 indicates poor but improvable, and >1.50 indi-
cates poor flowability of the powder.24 The results show 
that the HR of all the formulations was in the range from 
1.03 ±0.02 to 1.32 ±0.22 (Table 2), which indicates good 
flow properties of powder blends.
Void volume 
The void volume was found in the range from 0.3 ±0.18 
to 2.4 ±0.39 (Table 2), indicating that the powder blend 
had good flow properties.
Evaluation of rapidly disintegrating tablets 
General appearance 
All the tablets were white to off-white in color, round 
and flat in shape with a score line through the center, and 
had a smooth surface.
Table 2. Micrometric properties of powder blend 
Micrometric property
Formulation code
CPX1 CPX2 CPX3 CPX4 CPX5 CPX6 CPX7 CPX8 CPX9






























































































































































Data are presented as mean ± standard deviation (SD), n = 3.
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Uniformity of weight 
Twenty tablets were randomly selected from each 
batch for weight variation testing. The tablets were 
weighed individually and the average weight of 20 tablets 
was calculated. The results were within the range from 
198.40 ±0.01 mg to 200.41 ±0.12 mg (Table 3). The results 
were within the acceptable limit given in the USP.24
Thickness 
The thickness of the prepared tablets was found in the 
range from 2.0 ±0.56 mm to 2.99 ±0.05 mm (Table 3).
Hardness 
Tablet strength and disintegrating time depend on its 
hardness. It had been observed that the RDTs are less 
hard than conventional tablets because less compression 
force is applied. The hardness of the prepared tablets was 
in the range from 2.30 ±0.40 kg/cm² to 3.90 ±0.06 kg/cm², 
which is sufficient to maintain the tablet integrity during 
storage and handling and also within the range ensuring 
rapid disintegration (Table 3).
In vitro disintegrating and wetting time 
The in vitro tablet disintegration time is the time 
taken to undergo complete disintegration of the tablet 
in USP tablet disintegration apparatus under specified 
conditions. Disintegrating time is related to the nature 
and concentration of superdisintegrants and hardness 
of  the tablet. It allows breaking the tablet into small 
fragments upon contact with dissolution media. The 
in vitro disintegrating time of the prepared tablets was 
found to be between 15 s and 35 s. Formulations CPX4 
and CPX5 had better disintegrating time, i.e., 19 s and 
15 s, respectively. This might be due to the swelling 
and wicking mechanism (drawing water through capil-
lary action) of water penetration in tablets containing 
SSG.25
Wetting time is closely related to the inner core density 
and hardness of  the tablet. The wetting time of  the pre-
pared tablets was found to be between 12 s and 32 s. The 
wetting time of formulations CPX5 and CPX4 was 12 s and 
19 s, respectively. It has been found that with an increase 
in the concentration of  superdisintegrants, the wetting 
time is rapidly decreased. Figure 4 presents the relationship 
between disintegration time and wetting time of different 
RDTs. The relationship between wetting time and water 
absorption ratio of different RDTs is presented in Fig. 5.













CPX1 198.51 ±0.04 2.69 ±0.23 3.40 ±0.32 73.00 ±0.17 0.36 ±0.40
CPX2 200.41 ±0.12 2.00 ±0.56 3.90 ±0.06 65.33 ±0.45 0.26 ±0.21
CPX3 199.01 ±0.22 2.34 ±0.04 2.90 ±0.03 81.16 ±0.62 0.30 ±0.33
CPX4 200.03 ±0.30 2.43 ±0.08 3.80 ±0.02 91.66 ±0.98 0.34 ±0.26
CPX5 200.01±0.16 2.83 ±0.04 3.16 ±0.08 70.08 ±0.72 0.25 ±0.11
CPX6 198.40 ±0.01 2.16 ±0.07 2.90 ±0.04 85.00 ±0.09 0.26 ±0.18
CPX7 199.03 ±0.21 2.29 ±0.02 3.12 ±0.02 83.06 ±0.05 0.29 ±0.38
CPX8 200.04 ±0.12 2.99 ±0.05 3.20 ±0.12 108.33 ±0.68 0.34 ±0.26
CPX9 200.23 ±0.62 2.63 ±0.61 2.30 ±0.40 95.83 ±0.91 0.37 ±0.33
Data are presented as mean ± standard deviation (SD), n = 3.
Fig. 4. Relationship between wetting time and disintegration time of 
different rapidly disintegrating tablets (RDTs) (formulation CPX1–CPX9)
Fig. 5. Relationship between wetting time and water absorption ratio  
of different rapidly disintegrating tablets (RDTs) (formulation CPX1–CPX9)
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Water absorption ratio 
The water absorption ratio is used to determine the 
amount of water absorbed by the tablet. The water ab-
sorption ratio of  the RDTs was observed in the range 
from 65  ±0.45% to 108.33  ±0.68%. Formulated batches 
of  tablets CPX4, CPX8 and CPX9 absorbed more than 
90% of the water, while the other batches had less capac-
ity to absorb water (Table 3). The results indicated that 
SSG and CP had higher water absorption ratios when 
compared to the CMS.
Friability 
The friability of the prepared tablets was found to be-
tween 0.26 ±0.21% and 0.86 ±0.40%, which is within the 
acceptable limit of less than 1% (Table 3). The formulated 
tablets had good mechanical strength and can be handled 
without excessive care.
X-ray diffraction 
The tablets developed using the drug–β-CD complex 
did not show many characteristic peaks of the pure drug, 
indicating a molecular dispersion of the drug within the 
polymer matrix in amorphous form (Fig. 6).
Conclusions 
The prepared RDTs had ideal physical properties such 
as uniform weight, satisfactory hardness, better friability 
strength, less disintegration time, and rapid release profiles 
to be used as a RDDDS for the anti-allergic drug. In vitro 
release of levocetirizine followed first order kinetics. The 
prepared tablets can be used in dysphagia conditions.
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